These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6938305)

  • 1. A phase II study of aclacinomycin A in acute leukemia in adults.
    Yamada K; Nakamura T; Tsuruo T; Kitahara T; Maekawa T; Uzaka Y; Kurita S; Masaoka T; Takaku F; Hirota Y; Amaki I; Osamura S; Ito M; Nakano N; Oguro M; Inagaki J; Onozawa K
    Cancer Treat Rev; 1980 Dec; 7(4):177-82. PubMed ID: 6938305
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of aclacinomycin in acute leukemia and lymphosarcoma.
    Mathé G; Gil MA; Delgado M; Bayssas M; Gouveia J; Ribaud P; Machover D; Misset JL; de Vassal F; Schwarzenberg L; Jasmin C; Hayat M
    Recent Results Cancer Res; 1980; 74():217-22. PubMed ID: 6893752
    [No Abstract]   [Full Text] [Related]  

  • 3. Current status of Japanese studies with the new anthracycline antibiotic aclacinomycin A.
    Oki T; Takeuchi T; Oka S; Umezawa H
    Recent Results Cancer Res; 1980; 74():207-16. PubMed ID: 7003659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anthracycline antineoplastic drugs.
    Young RC; Ozols RF; Myers CE
    N Engl J Med; 1981 Jul; 305(3):139-53. PubMed ID: 7017406
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase I-II study of aclarubicin for treatment of acute myeloid leukaemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Benavides M; Lotz JP; Misset JL; de Vassal F; Tapiero H
    Eur J Haematol Suppl; 1987; 47():33-42. PubMed ID: 3471523
    [No Abstract]   [Full Text] [Related]  

  • 6. Aclarubicin in the treatment of relapsed or resistant acute myelogenous leukaemia: a phase II trial.
    Evensen SA; Wisløff F; Müller E; Talstad I; Waage A; Johansen L
    Eur J Haematol Suppl; 1987; 47():43-7. PubMed ID: 3471524
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II evaluation of aclacinomycin-A (NSC-208734) in adenocarcinoma of the kidney.
    Decker DA; Drelichman A; Opipari MI; Al-Sarraf M
    Am J Clin Oncol; 1984 Oct; 7(5):527-8. PubMed ID: 6594927
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical studies of aclacinomycin A (ACM).
    Majima H; Ohta K
    Biomed Pharmacother; 1987; 41(5):233-7. PubMed ID: 3311189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aclacinomycin A.
    Oka S; Mathé G; Mitrou PS
    Cancer Treat Rev; 1984 Dec; 11(4):299-302. PubMed ID: 6598408
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II evaluation of aclacinomycin-A in advanced ovarian carcinoma.
    Martino S; Decker DA; Hynes HE; Kresge CL
    Invest New Drugs; 1987 Dec; 5(4):373-4. PubMed ID: 3481362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of aclacinomycin A in acute leukemia and various solid tumors.
    Schütte J; Niederle N; Seeber S
    J Cancer Res Clin Oncol; 1983; 105(2):162-5. PubMed ID: 6572190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
    Warrell RP; Arlin ZA; Kempin SJ; Young CW
    Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias.
    Mitrou PS; Kuse R; Anger H; Herrmann R; Bonfert B; Pralle H; Thiel E; Westerhausen M; Mainzer K; Bartels H
    Eur J Cancer Clin Oncol; 1985 Aug; 21(8):919-23. PubMed ID: 3862584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of acute leukemia: contribution of the new anthracyclinic drugs].
    Lambertenghi-Deliliers G; Colajori E; Annaloro C; Polli EE
    Recenti Prog Med; 1985; 76(7-8):392-7. PubMed ID: 3906794
    [No Abstract]   [Full Text] [Related]  

  • 15. [Aclacinomycin-A in acute leukaemias and leukaemic non-Hodgkin lymphomas (author's transl)].
    Mathé G; de Jager R; Hulhoven R; Delgado M; Machover D; Ribaud P; de Vassal F; Gil-Delgado M; Misset JL; Gouveia J; Jasmin C; Hayat M; Gastiaburu J; Schwarzenberg L
    Nouv Presse Med; 1982 Jan; 11(1):25-8. PubMed ID: 6949137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
    Haruyama H; Shimazaki C; Nakanishi S; Hamami T; Nisio A; Isemura T; Katsume H; Nakagawa M; Ijichi H
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):516-21. PubMed ID: 6964037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aclacinomycin. Phase II evaluation in advanced squamous carcinoma of the head and neck.
    Kish JA; Al-Sarraf M
    Am J Clin Oncol; 1984 Oct; 7(5):535-7. PubMed ID: 6507374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of aclarubicin in epidermoid carcinoma of the head and neck.
    Carugati AA; Olivari AJ; Campos DM; Pradier R; Woolley PV
    Cancer Treat Rep; 1986 Jun; 70(6):799-800. PubMed ID: 3524828
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study.
    Karanes C; Young JD; Samson MK; Smith LB; Franco LA; Baker LH
    Invest New Drugs; 1983; 1(2):173-9. PubMed ID: 6590531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aclarubicin in single agent and combined chemotherapy of acute myeloid leukaemias.
    Mitrou PS
    Eur J Haematol Suppl; 1987; 47():59-66. PubMed ID: 3471526
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.